BG
LCTX icon

BlackRock Group’s Lineage Cell Therapeutics LCTX Stock Holding History

BlackRock Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$179K Buy
56,974
+14,020
+33% +$43K ﹤0.01% 2692
2016
Q3 		$146K Hold
42,954
– – ﹤0.01% 2728
2016
Q2 		$98K Hold
42,954
– – ﹤0.01% 2797
2016
Q1 		$108K Buy
42,954
+36,270
+543% +$80.9K ﹤0.01% 2742
2015
Q4 		$22K Hold
6,684
– – ﹤0.01% 2929
2015
Q3 		$16K Buy
+6,684
New +$17.3K ﹤0.01% 3000

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock Group's LCTX Position: Q4 2016 in Review

BlackRock Group increased its Lineage Cell Therapeutics (LCTX) stake by 33% in Q4 2016, buying an estimated $43K and bringing the position to 56,974 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

BlackRock Group first reported a position in LCTX in Q3 2015 and has held it in 6 quarters since. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • BlackRock Group held 56,974 shares of Lineage Cell Therapeutics worth $179K as of Q4 2016.
  • BlackRock Group bought 14,020 Lineage Cell Therapeutics shares in Q4 2016, an estimated $43K.
  • Lineage Cell Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2692 holding.
  • BlackRock Group first reported a position in Lineage Cell Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.